Epidermal growth factor receptor (EGFR), evaluated by immunohistochemistry, has been shown to have prognostic significance in patients with colorectal cancer. Gene copy number (GCN) of EGFR and KRAS status predict response and outcome in patients treated with anti-EGFR therapy, but their prognostic significance in colorectal cancer patients is still unclear.We have retrospectively reviewed the baseline EGFR GCN, KRAS status and clinical outcome of 146 locally advanced rectal cancer (LARC) patients treated with preoperative chemoradiotherapy. Pathological response evaluated by Dworak's tumour regression grade (TRG), disease-free survival (DFS) and overall survival (OS) were analysed.Tumour regression grade 4 and TRG3-4 were achieved in 14.4 and 30.8\% of the patients respectively. Twenty-nine (19.9\%) and 33 patients (19.2\%) had an EGFR/nuclei ratio >2.9 and CEP7 polisomy >50\% respectively; 28 patients (19.2\%) had a KRAS mutation. Neither EGFR GCN nor KRAS status was statistically correlated to TRG. 5-year DFS and OS were 63.3 and 71.5\%, respectively, and no significant relation with EGFR GCN or KRAS status was found.Our data show that EGFR GCN and KRAS status are not prognostic factors in LARC treated with preoperative chemoradiation.

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy / C., Bengala; Bettelli, Stefania Raffaella; F., Bertolini; G., Sartori; Fontana, Annalisa; N., Malavasi; R., Depenni; S., Zironi; DEL GIOVANE, Cinzia; G., Luppi; Conte, Pierfranco. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - STAMPA. - 103:(2010), pp. 1019-1024. [10.1038/sj.bjc.6605853]

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.

BETTELLI, Stefania Raffaella;FONTANA, Annalisa;DEL GIOVANE, Cinzia;CONTE, Pierfranco
2010

Abstract

Epidermal growth factor receptor (EGFR), evaluated by immunohistochemistry, has been shown to have prognostic significance in patients with colorectal cancer. Gene copy number (GCN) of EGFR and KRAS status predict response and outcome in patients treated with anti-EGFR therapy, but their prognostic significance in colorectal cancer patients is still unclear.We have retrospectively reviewed the baseline EGFR GCN, KRAS status and clinical outcome of 146 locally advanced rectal cancer (LARC) patients treated with preoperative chemoradiotherapy. Pathological response evaluated by Dworak's tumour regression grade (TRG), disease-free survival (DFS) and overall survival (OS) were analysed.Tumour regression grade 4 and TRG3-4 were achieved in 14.4 and 30.8\% of the patients respectively. Twenty-nine (19.9\%) and 33 patients (19.2\%) had an EGFR/nuclei ratio >2.9 and CEP7 polisomy >50\% respectively; 28 patients (19.2\%) had a KRAS mutation. Neither EGFR GCN nor KRAS status was statistically correlated to TRG. 5-year DFS and OS were 63.3 and 71.5\%, respectively, and no significant relation with EGFR GCN or KRAS status was found.Our data show that EGFR GCN and KRAS status are not prognostic factors in LARC treated with preoperative chemoradiation.
2010
103
1019
1024
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy / C., Bengala; Bettelli, Stefania Raffaella; F., Bertolini; G., Sartori; Fontana, Annalisa; N., Malavasi; R., Depenni; S., Zironi; DEL GIOVANE, Cinzia; G., Luppi; Conte, Pierfranco. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - STAMPA. - 103:(2010), pp. 1019-1024. [10.1038/sj.bjc.6605853]
C., Bengala; Bettelli, Stefania Raffaella; F., Bertolini; G., Sartori; Fontana, Annalisa; N., Malavasi; R., Depenni; S., Zironi; DEL GIOVANE, Cinzia; G., Luppi; Conte, Pierfranco
File in questo prodotto:
File Dimensione Formato  
6605853.pdf

Open access

Descrizione: hybrid gold OA
Tipologia: Versione pubblicata dall'editore
Dimensione 247.83 kB
Formato Adobe PDF
247.83 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/739292
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 35
social impact